CSIMarket Company Name, Ticker, Suppliers, else..
 
Aravive Inc   (NASDAQ: ARAV)
Other Ticker:  
 
 
Price: $0.0401 $-0.01 -13.391%
Day's High: $0.046 Week Perf: -17.32 %
Day's Low: $ 0.04 30 Day Perf: -68.75 %
Volume (M): 4,040 52 Wk High: $ 0.00
Volume (M$): $ 162 52 Wk Avg: $0.00
Open: $0.04 52 Wk Low: $0.00



 Market Capitalization (Millions $) 3
 Shares Outstanding (Millions) 76
 Employees 31
 Revenues (TTM) (Millions $) 7
 Net Income (TTM) (Millions $) -40
 Cash Flow (TTM) (Millions $) -45
 Capital Exp. (TTM) (Millions $) 0

Aravive Inc
Aravive Inc is a biopharmaceutical company that focuses on developing innovative therapies to treat serious diseases, particularly in the field of oncology and fibrosis. The company is committed to discovering and developing novel drugs that target specific proteins and pathways involved in the progression of these diseases. Aravive's approach combines scientific expertise, advanced technologies, and strategic partnerships to accelerate the development of potential therapies. The company's ultimate goal is to improve the lives of patients worldwide by providing effective and targeted treatment options.


   Company Address: 3730 Kirby Drive, Suite 1200 Houston 77098 TX
   Company Phone Number: 355-1910   Stock Exchange / Ticker: NASDAQ ARAV


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ACRS        3.18% 
FGEN        1.07% 
MEIP        0.43% 
URGN   -4.16%    
XNCR   -16.21%    
ZLAB        1.94% 
• View Complete Report
   



Aravive Inc

ARA-Vive: Witness the Spectacular Revenue Slump, Stirring Ripples Along the Fiscal Interval Ending Sep 30, 2023

Aravive Inc. Turns a Corner, Propelling the Stock Market Forward
In a remarkable comeback, Aravive Inc. (ARAV) has announced a significant turnaround in its financial performance. The company has posted impressive earnings per share (EPS) of $0.28, a notable improvement from the loss of $-0.51 per share in the previous year. Moreover, income per share has drastically turned positive, leaping from $-0.12 per share to a positive figure in the most recent reporting season. These astonishing results have undoubtedly caught the attention of investors worldwide.
The company's revenue may have experienced a decline of -44.391%, falling to $2.76 million from the previous year's $4.96 million. However, it is important to note that the sequential revenue demonstrates a remarkable 116.327% increase, surging from $1.27 million. This sudden boost in revenue indicates a positive shift in the market demand for Aravive Inc.'s products and services.
Aravive Inc

Aravive Inc's Top-line Takes a Dramatic Dive, Witnessing a 20.43% Drop in Stock Amidst Challenging Fiscal Period

During the past 5 trading days, Aravive Inc stock experienced a significant drop of -20.43%. This decline adds to the overall poor performance of the company, with a year-to-date performance of -87.86%. The stock has now reached its 52-week low, indicating a difficult period for the company.
To gain a better understanding of Aravive Inc's situation, it is essential to examine its financial performance. For the fiscal span between April and June 30, 2023, the company reported a decrease in loss per share from $-0.61 to $-0.12 compared to the previous year. Additionally, the earnings per share improved to $-0.66 from the preceding reporting season.
Aravive Inc

Aravive Inc's Phenomenal 36.538% Revenue Surge Shatters Expectations Amidst Challenging Fiscal Period

Aravive Inc, a major player in the pharmaceutical industry, has reported a deficit per share of $-0.66 for its most recent fiscal period, which is a significant increase from the deficit of $-0.40 per share in the previous reporting period. Despite this, the company's revenue saw a surge of 36.538% to $1.49 million during the same period from a year ago.
This growth in revenue can be attributed to the steady demand for the company's pharmaceutical preparations, which have gained widespread recognition among medical professionals and patients alike. However, despite this growth in revenue, Aravive Inc continues to suffer losses, as evident from its deficit per share.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com